Monte Rosa Therapeutics (GLUE) Return on Sales (2024 - 2026)

Monte Rosa Therapeutics' Return on Sales history runs 3 years deep, the most recent figure standing at 0.1% for Q1 2026.

• On a quarterly basis, Return on Sales fell 11.0% year-over-year to 0.1% in Q1 2026; TTM through Mar 2026 was 0.26%, a 27.0% decrease from a year earlier, with the FY2025 full-year figure at 0.0%, up 1.0% from the prior year.
• Return on Sales grew to 0.1% in Q1 2026 per GLUE's latest filing, from 0.11% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q1 2025 and bottomed at 0.3% in Q1 2024.
• The 3-year median for Return on Sales is 0.03% (2024), against an average of 0.07%.
• Biggest YoY gain for Return on Sales was 31 bps in 2025; the steepest drop was 11 bps in 2025.
• Year by year, Return on Sales stood at 0.01% in 2024, then plunged by 2192 bps to 0.11% in 2025, then gained by 2 bps to 0.1% in 2026.
• Per Business Quant, the three latest GLUE Return on Sales figures stand at 0.1% (Q1 2026), 0.11% (Q4 2025), and 0.0% (Q3 2025).